| Title | Current management of chemotherapy-induced neutropenia in adults: key points and new challenges |
| Authors | Yi Ba Yuankai Shi Wenqi Jiang Jifeng Feng Ying Cheng Li Xiao Qingyuan Zhang Wensheng Qiu Binghe Xu Ruihua Xu Bo Shen Zhiguo Luo Xiaodong Xie Jianhua Chang Mengzhao Wang Yufu Li Yuerong Shuang Zuoxing Niu Bo Liu Jun Zhang Li Zhang Herui Yao Conghua Xie Huiqiang Huang Wangjun Liao Gongyan Chen Xiaotian Zhang Hanxiang An Yanhong Deng Ping Gong Jianping Xiong Qinghua Yao Xin An Cheng Chen Yanxia Shi Jialei Wang Xiaohua Wang Zhiqiang Wang Puyuan Xing Sheng Yang Chenfei Zhou |
| Affiliation | Committee of Neoplastic Supportive-Care (CONS),China Anti-Cancer Association Committee of Clinical Chemotherapy,China Anti-Cancer Association Department of Gastrointestinal Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer Department of Medical Oncology,National Cancer Center,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Department of Medical Oncology,Sun Yat-sen University Cancer Center Department of Medical Oncology,Jiangsu Cancer Hospital Department of Oncology,Jilin Province Cancer Hospital Department of Oncology,Zhongshan Hospital Affiliated to Xiamen University Department of Oncology,Cancer Hospital Harbin Medical University Department of Oncology,Affiliated Hospital of Qingdao University Department of Medical Oncology,Fudan University Shanghai Cancer Center Department of Oncology,General Hospital of Shenyang Military Region Department of Pulmonary and Critical Care Medicine,Peking Union Medical College Hospital Department of Hematology,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital Lymphoma and Myeloma Department,Jiangxi Cancer Hospital Department of Medical Oncology,Shandong Cancer Hospital,Shandong Academy of Medical Sciences Department of Oncology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine Sun Yat-sen Memorial Hospital,Sun Yat-sen University Department of Radiation and Medical Oncology,Zhongnan Hospital of Wuhan University Department of Oncology,Nanfang Hospital,Southern Medical University Department of Gastrointestinal Oncology,Peking University Cancer Hospital & Institute Department of Medical Oncology,Xiang'an Hospital of Xiamen University Department of Medical Oncology,The Sixth Affiliated Hospital,Sun Yat-sen University Department of Oncology,The First Affiliated Hospital,Shihezi University School of Medicine Department of Oncology,The First Affiliated Hospital of Nanchang University Department of Integrated Chinese and Western Medicine,Cancer Hospital of University of Chinese Academy of Science,Zhejiang Cancer Hospital |
| Keywords | Chemotherapy-induced neutropenia(CIN) febrile neutropenia cancer risk stratification granulocyte-colony stimulating factor(G-CSF) |
| Issue Date | 15-Nov-2020 |
| Publisher | Cancer Biology & Medicine |
| Abstract | Chemotherapy-induced neutropenia(CIN) is a potentially fatal and common complication in myelosuppressive chemotherapy. The timing and grade of CIN may play prognostic and predictive roles in cancer therapy. CIN is associated with older age, poor functional and nutritional status, the presence of significant comorbidities, the type of cancer, previous chemotherapy cycles, the stage of the disease, specific chemotherapy regimens, and combined therapies. There are many key points and new challenges in the management of CIN in adults including:(1) Genetic risk factors to evaluate the patient's risk for CIN remain unclear. However, these risk factors urgently need to be identified.(2) Febrile neutropenia(FN) remains one of the most common reasons for oncological emergency. No consensus nomogram for FN risk assessment has been established.(3) Different assessment tools [e.g., Multinational Association for Supportive Care in Cancer(MASCC), the Clinical Index of Stable Febrile Neutropenia(CISNE) score model, and other tools] have been suggested to help stratify the risk of complications in patients with FN. However, current tools have limitations. The CISNE score model is useful to support decision-making, especially for patients with stable FN.(4) There are still some challenges, including the benefits of granulocyte colony stimulating factor treatment and the optimal antibiotic regimen in emergency management of FN. In view of the current reports, our group discusses the key points, new challenges, and management of CIN. |
| URI | http://hdl.handle.net/20.500.11897/598230 |
| ISSN | 2095-3941 |
| DOI | 10.20892/j.issn.2095-3941.2020.0069 |
| Indexed | SCI(E) 中国科学引文数据库(CSCD) |
| Appears in Collections: | 北京肿瘤医院 |
